Investment Thesis:
- The stock is trading below our valuation and represents >10% upside to the current share price.
- Proven and market leading technology (management believes they are 24 months ahead of competitors), with PME’s product commanding a price premium.
- New contract wins (more win rates plus higher value per contract) and increasing usage by existing clients.
- New product launches – Enterprise Imaging solutions and moving into other “ologies” such as cardiology and ophthalmology. Developing artificial intelligence (AI) capabilities.
- Leveraged to the digital health data thematic and industry’s transition to cloud.
- Expansion into new geographies.
- Potential M&A activity.
Key Risks:
- High valuation which subjects the stock price to more volatility.
- Timing (long lead time to close contracts) and scale of new contract wins disappoints relative to market expectations.
- Contract renewals (pricing pressure) and potential budget cuts at hospitals leading to the delay of software upgrades / investment.
- Increasing competitive pressures (from large scale players and new entrants with innovative technology).
- Systems reliability – data breach or drop in quality.
- Regulatory / funding changes – reimbursement changes leading to lower imaging volumes.
Key Highlights:
- Pro Medicus Ltd (PME) reported strong 1H22 results reflecting earnings (net profit) of $20.68m, up +52.7% relative to the pcp.
- Revenue was up +40.3% to $44.33m driven by contract wins and renewals in the U.S. and an extension of a European contract to cover new regions.
- Underlying profit before tax $28.8m, up +53.5%
- Net profit of $20.68m, up +52.7%.
- PME retained a strong balance sheet with cash reserves of $76.17m, up $14.91m and remains debt-free.
- PME reported key contract wins which bodes well for future earnings: Novant Health (A$40m, 7-year contract), a community-based integrated delivery network that spans three U.S. states; Contract renewal with Allegheny Health (A$12m, 5-year), a health network in Pittsburgh, Pennsylvania; and extension of German government hospital to a fourth site.
- Management also highlighted PME made progress with all key implementations being on or ahead of schedule, including Intermountain and UCSF.
- The Board declared a fully franked interim dividend of 10c per share, up +42.9%.
Company Description:
Pro Medicus Ltd (PME) was founded in 1983 and provides a full range of radiology IT software and services to hospitals, imaging centers and health care groups globally. In Jan-09, PME purchased Visage Imaging, which has become a global provider of leading-edge enterprise imaging solutions, pioneering the best-of-breed, or Deconstructed PACSSM enterprise imaging strategy. Visage 7 technology delivers fast, multi-dimensional images streamed via an intelligent thin-client viewer. The company offers a leading suite of RIS, PACS and e-health solutions constituting one of the most comprehensive end-to-end offerings in radiology. Pro Medicus has global offices in Melbourne, Berlin (R&D) and San Diego (Sales).
(Source: Banyantree)
General Advice Warning
Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.